TAK FY 2018 Earnings Report — Takeda Pharmaceutical Company Limited Revenue & Financial Results | Market Cap Arena

Takeda Pharmaceutical Company LimitedTAK

FY 2018 Earnings

Reported March 30, 2019

Quarter Comparison

Revenue

Operating Income

Gross Margin

Net Margin

EPS (Diluted)

Free Cash Flow

Metric	FY 2018	Prior Q	FY 2017	QoQ Change	YoY Change
Revenue	$13.1B	—	$11.1B	—	18.5%
Op. Income	$1.3B	—	$1.5B	—	-15.2%
Gross Margin	68.5%	—	72.0%	—	-3.4pp
Net Margin	5.2%	—	10.6%	—	-5.4pp
EPS (Diluted)	$0.22	—	$0.74	—	-70.7%
Free Cash Flow	$1.2B	—	$1.6B	—	-22.1%

Revenue Flow

Item	Amount
REVENUE	$13.1B
Cost of Revenue	$4.1B
GROSS PROFIT	$9.0B
R&D Expenses	$2.3B
Selling & Marketing	$0
General & Administrative	$0
SG&A Expenses	$4.5B
Other Expenses	$5.7B
Operating Expenses	$8.0B
Cost & Expenses	$12.1B
OPERATING INCOME	$1.3B
Interest Income	$41M
Interest Expense	$302M
Other Income/Expenses	-$690M
INCOME BEFORE TAX	$595M
Income Tax Expense	-$88M
Net Income from Continuing Ops	$846M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$684M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$847M
D&A	$1.6B
EBIT	$1.1B
EBITDA	$2.9B
EPS	$0
EPS Diluted	$0

Income Statement

Item	Amount
REVENUE	$13.1B
Cost of Revenue	$4.1B
GROSS PROFIT	$9.0B
R&D Expenses	$2.3B
Selling & Marketing	$0
General & Administrative	$0
SG&A Expenses	$4.5B
Other Expenses	$5.7B
Operating Expenses	$8.0B
Cost & Expenses	$12.1B
OPERATING INCOME	$1.3B
Interest Income	$41M
Interest Expense	$302M
Other Income/Expenses	-$690M
INCOME BEFORE TAX	$595M
Income Tax Expense	-$88M
Net Income from Continuing Ops	$846M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$684M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$847M
D&A	$1.6B
EBIT	$1.1B
EBITDA	$2.9B
EPS	$0
EPS Diluted	$0

Cash Flow Statement

Item	Amount
Net Income	$683M
Depreciation & Amortization	$1.7B
Stock-Based Compensation	$126M
Deferred Income Tax	-$88M
Other Non-Cash Items	-$845M
Change in Working Capital	$476M
OPERATING CASH FLOW	$2.1B
Capital Expenditure	-$840M
Acquisitions (Net)	-$18.0B
Purchases of Investments	-$107M
Sales/Maturities of Investments	$407M
Other Investing Activities	$777M
NET CASH FROM INVESTING	-$17.8B
Net Debt Issuance	$19.8B
Common Stock Repurchased	-$7M
Common Dividends Paid	-$896M
Other Financing Activities	-$446M
NET CASH FROM FINANCING	$18.5B
FREE CASH FLOW	$1.2B
Net Change in Cash	$2.6B

Balance Sheet

Item	Amount
Cash & Equivalents	$4.4B
Short-Term Investments	$146M
Net Receivables	$4.7B
Inventory	$6.2B
Other Current Assets	$3.8B
TOTAL CURRENT ASSETS	$19.1B
PP&E (Net)	$8.2B
Goodwill	$26.1B
Intangible Assets	$30.5B
Long-Term Investments	$1.9B
Tax Assets	$558M
Other Non-Current Assets	$548M
TOTAL NON-CURRENT ASSETS	$67.7B
TOTAL ASSETS	$86.9B
Account Payables	$1.3B
Short-Term Debt	$6.2B
Deferred Revenue	$0
Other Current Liabilities	$6.8B
TOTAL CURRENT LIABILITIES	$15.7B
Long-Term Debt	$29.9B
Deferred Revenue NC	$0
Deferred Tax Liabilities	$4.5B
Other Non-Current Liabilities	$3.5B
TOTAL NON-CURRENT LIABILITIES	$38.8B
TOTAL LIABILITIES	$54.6B
Common Stock	$10.3B
Additional Paid-In Capital	$10.3B
Retained Earnings	$9.8B
Treasury Stock	-$358M
Accum. Other Comp. Income	$2.2B
Other Equity	$0
TOTAL STOCKHOLDERS' EQUITY	$32.3B
Minority Interest	$25M
TOTAL EQUITY	$32.3B
TOTAL LIABILITIES & EQUITY	$86.9B
Total Debt	$36.0B
Net Debt	$31.6B